Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.
Zhenggang Ren(Ministry of Education of the People's Republic of China), Stephen L. Chan(Chinese University of Hong Kong), Aibing Xu(Nantong Tumor Hospital), Shanzhi Gu(Central South University), Ruijun Xing, Chunyi Hao(Peking University), Yuxian Bai(Harbin Medical University), Wěi Li(Zhengzhou University), Xinyu Zhang, Jian Zhang(Zhujiang Hospital), Dan Zhang(Kunming Municipal Hospital of Traditional Chinese Medicine), Zhendong Chen(Anhui Medical University), Jingdong Zhang(Fudan University Shanghai Cancer Center), Zhiqiang Meng(Shanghai Medical College of Fudan University), Yabing Guo, Jun Liang(Zhejiang Chinese Medical University), Xinfang Hou(Zhengzhou University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 25
Related Papers
NF-κB in biology and targeted therapy: new insights and translational implications
|Signal Transduction and Targeted Therapy|2024|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
|Proceedings of the National Academy of Sciences|2015|755